{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:14:15Z","timestamp":1794334455999,"version":"4.9.0"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012411","name":"Alborz University of Medical Sciences","doi-asserted-by":"publisher","award":["99-4183"],"award-info":[{"award-number":["99-4183"]}],"id":[{"id":"10.13039\/501100012411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.intimp.2021.107565","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T13:57:21Z","timestamp":1616594241000},"page":"107565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["The clinical efficacy of Rituximab administration in autoimmunity disorders, primary immunodeficiency diseases and malignancies"],"prefix":"10.1016","volume":"95","author":[{"given":"Zeineb","family":"Zian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.P. D\u00e9o-Gracias","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9956-3644","authenticated-orcid":false,"given":"Nazila","family":"Bahmaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9676-0404","authenticated-orcid":false,"given":"Dana","family":"Ghotbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Kashif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Madkaikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umair Ahmed","family":"Bargir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5910-8735","authenticated-orcid":false,"given":"Hamisu","family":"Abdullahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroon","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gholamreza","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2021.107565_b0005","first-page":"233","article-title":"Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: report of four cases","volume":"18","author":"M","year":"2013","journal-title":"Hematol. Amst. Neth."},{"issue":"7","key":"10.1016\/j.intimp.2021.107565_b0010","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3174\/ajnr.A2142","article-title":"Rituximab (Rituxan)","volume":"31","author":"Selewski","year":"2010","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"7","key":"10.1016\/j.intimp.2021.107565_b0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw. Open"},{"issue":"15","key":"10.1016\/j.intimp.2021.107565_b0020","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.2217\/fon.14.146","article-title":"Rituximab: modes of action, remaining dispute and future perspective","volume":"10","author":"Abulayha","year":"2014","journal-title":"Future Oncol."},{"issue":"16","key":"10.1016\/j.intimp.2021.107565_b0025","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1182\/blood-2011-03-344051","article-title":"Immunologic effects of rituximab on the human spleen in immune thrombocytopenia","volume":"118","author":"Audia","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.intimp.2021.107565_b0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40744-015-0016-9","article-title":"Rituximab for rheumatoid arthritis","volume":"2","author":"Cohen","year":"2015","journal-title":"Rheumatol. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2021.107565_b0035","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2141.2011.08880.x","article-title":"Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients","volume":"155","author":"Gobert","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.intimp.2021.107565_b0040","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3324\/haematol.2014.114561","article-title":"Treatment of autoimmune hemolytic anemias","volume":"99","author":"Zanella","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.intimp.2021.107565_b0045","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.intimp.2021.107565_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577317","article-title":"Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis","volume":"347","author":"Tian","year":"2020","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107565_b0055","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000501538","article-title":"A retrospective study of the combination of rituximab, cyclophosphamide and dexamethasone for the treatment of relapsed\/refractory warm antibody autoimmune hemolytic anemia","volume":"143","author":"Piatek","year":"2020","journal-title":"Acta Haematol."},{"issue":"4","key":"10.1016\/j.intimp.2021.107565_b0060","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jaci.2013.01.046","article-title":"B-cell biology and development","volume":"131","author":"Pieper","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2021.107565_b0065","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0092-8674(00)80165-8","article-title":"Definitive hematopoiesis is autonomously initiated by the AGM region","volume":"86","author":"Medvinsky","year":"1996","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.intimp.2021.107565_b0070","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/1074-7613(94)90081-7","article-title":"Development of hematopoietic stem cell activity in the mouse embryo","volume":"1","author":"M\u00fcller","year":"1994","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2021.107565_b0075","series-title":"Immunologie","author":"Espinosa","year":"2010"},{"key":"10.1016\/j.intimp.2021.107565_b0080","first-page":"13","article-title":"The mechanism of V(D)J recombination","author":"Little","year":"2015"},{"key":"10.1016\/j.intimp.2021.107565_b0085","doi-asserted-by":"crossref","unstructured":"S. Sadanand, M.M. Tomayko, B cell biology, in: A.A. Gaspari, S. K. Tyring, D. H. Kaplan (\u00c9ds.), Clinical and Basic Immunodermatology, Springer International Publishing, Cham, 2017, pp. 97\u2013119.","DOI":"10.1007\/978-3-319-29785-9_7"},{"issue":"2","key":"10.1016\/j.intimp.2021.107565_b0090","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)80472-0","article-title":"Precursor B cells showing H chain allelic inclusion display allelic exclusion at the level of pre-B cell receptor surface expression","volume":"8","author":"ten Boekel","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2021.107565_b0095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1600-065X.2000.imr017510.x","article-title":"Repertoire selection by pre-B-cell receptors and B-cell receptors, and genetic control of B-cell development from immature to mature B cells","volume":"175","author":"Melchers","year":"2000","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2021.107565_b0100","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nri1633","article-title":"Transcriptional networks in developing and mature B cells","volume":"5","author":"Matthias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2021.107565_b0105","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.3389\/fimmu.2018.02423","article-title":"The role of the pre-B cell receptor in B cell development, repertoire selection, and tolerance","volume":"9","author":"Winkler","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107565_b0110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4049\/jimmunol.180.1.361","article-title":"Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice","volume":"180","author":"DiLillo","year":"2008","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2021.107565_b0115","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri1886","article-title":"Competence and competition: the challenge of becoming a long-lived plasma cell","volume":"6","author":"Radbruch","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2021.107565_b0120","unstructured":"B. Fr\u00e9d\u00e9ric, G. Olivier, P. Lionel, R. Yves, V. Laurent, Lymphocytes B\u00a0: diversit\u00e9 ontog\u00e9n\u00e8se, diff\u00e9renciation et activation, in: Immunologie Fondamentale et immunopathologie, Enseignements th\u00e9matiques et int\u00e9gr\u00e9\u00a0; le cours QCM corrig\u00e9s, Elsevier Masson, 2013, pp. 41\u201352."},{"key":"10.1016\/j.intimp.2021.107565_b0125","doi-asserted-by":"crossref","unstructured":"B Cell Memory and Plasma Cell Development, in: Molecular Biology of B Cells, Elsevier, 2015, pp. 227\u2013249.","DOI":"10.1016\/B978-0-12-397933-9.00014-X"},{"issue":"1","key":"10.1016\/j.intimp.2021.107565_b0130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/25785826.2019.1698929","article-title":"B cells targeting therapy in the management of systemic lupus erythematosus","volume":"43","author":"Lee","year":"2020","journal-title":"Immunol. Med."},{"key":"10.1016\/j.intimp.2021.107565_b0135","series-title":"Thyroid disease and autoimmune diseases","author":"Franco","year":"2013"},{"issue":"4","key":"10.1016\/j.intimp.2021.107565_b0140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1297\/cpe.23.99","article-title":"Type 1 diabetes and autoimmunity","volume":"23","author":"Kawasaki","year":"2014","journal-title":"Clin. Pediatr. Endocrinol."},{"issue":"10","key":"10.1016\/j.intimp.2021.107565_b0145","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.3748\/wjg.v20.i10.2606","article-title":"Autoantibodies in primary biliary cirrhosis: recent progress in research on the pathogenetic and clinical significance","volume":"20","author":"Yamagiwa","year":"2014","journal-title":"World J. Gastroenterol. WJG"},{"key":"10.1016\/j.intimp.2021.107565_b0150","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fimmu.2020.00240","article-title":"New approaches to targeting B cells for myasthenia gravis therapy","volume":"11","author":"Huda","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2021.107565_b0155","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coi.2016.09.003","article-title":"Targeting B cells in treatment of autoimmunity","volume":"43","author":"Franks","year":"2016","journal-title":"Curr. Opin. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2021.107565_b0160","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ncprheum0895","article-title":"Nature and functions of autoantibodies","volume":"4","author":"Elkon","year":"2008","journal-title":"Nat. Clin. Pract. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107565_b0165","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3233\/JND-170294","article-title":"New pathways and therapeutic targets in autoimmune myasthenia gravis","volume":"5","author":"Behin","year":"2018","journal-title":"J. Neuromuscul. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2021.107565_b0170","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"10.1016\/j.intimp.2021.107565_b0175","first-page":"804","article-title":"Strategies for treating autoimmune disease with monoclonal antibodies","volume":"143","author":"Wofsy","year":"1985","journal-title":"West. J. Med."},{"issue":"11","key":"10.1016\/j.intimp.2021.107565_b0180","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1517\/14712598.2010.524923","article-title":"Targeting B cells with biologics in systemic lupus erythematosus","volume":"10","author":"La Cava","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"issue":"21","key":"10.1016\/j.intimp.2021.107565_b0185","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1056\/NEJMct1114348","article-title":"Anti-CD20 antibody therapy for B-cell lymphomas","volume":"366","author":"Maloney","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2021.107565_b0190","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.intimp.2021.107565_b0195","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1111\/ajt.14872","article-title":"Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody","volume":"18","author":"Ristov","year":"2018","journal-title":"Am. J. Transplant."},{"issue":"5","key":"10.1016\/j.intimp.2021.107565_b0200","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4161\/mabs.3.5.16983","article-title":"Neonatal Fc receptor and IgG-based therapeutics","volume":"3","author":"Kuo","year":"2011","journal-title":"mAbs"},{"issue":"3","key":"10.1016\/j.intimp.2021.107565_b0205","first-page":"143","article-title":"Anti-CD19 monoclonal antibodies: a new approach to lymphoma therapy","volume":"4","author":"Naddafi","year":"2015","journal-title":"Int. J. Mol. Cell. Med."},{"issue":"4","key":"10.1016\/j.intimp.2021.107565_b0210","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.leukres.2007.07.002","article-title":"Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in pre-B acute lymphoblastic leukemia cell lines","volume":"32","author":"Stanciu-Herrera","year":"2008","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.intimp.2021.107565_b0215","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-14-2291","article-title":"Interleukin-6 as a therapeutic target","volume":"21","author":"Rossi","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2021.107565_b0220","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2021.107565_b0225","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2567.2005.02225.x","article-title":"Therapeutic anti-integrin (\u03b14 and \u03b1L) monoclonal antibodies: two-edged swords?","volume":"116","author":"Gonz\u00e1lez-Amaro","year":"2005","journal-title":"Immunology"},{"issue":"12","key":"10.1016\/j.intimp.2021.107565_b0230","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2174\/1567205015666180801111033","article-title":"Anti-\u03b14\u03b21 integrin antibodies attenuated brain inflammatory changes in a mouse model of Alzheimer\u2019s disease","volume":"15","author":"Manocha","year":"2018","journal-title":"Curr. Alzheimer Res."},{"issue":"6","key":"10.1016\/j.intimp.2021.107565_b0235","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.coi.2010.09.010","article-title":"Targeting BAFF in autoimmunity","volume":"22","author":"Davidson","year":"2010","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107565_b0240","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41232-016-0015-4","article-title":"BAFF-, and APRIL-targeted therapy in systemic autoimmune diseases","volume":"36","author":"Nakayamada","year":"2016","journal-title":"Inflamm. Regen."},{"issue":"4","key":"10.1016\/j.intimp.2021.107565_b0245","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4155\/fmc-2019-0299","article-title":"Immunoproteasome-selective inhibitors: the future of autoimmune diseases?","volume":"12","author":"Zhang","year":"2020","journal-title":"Future Med. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2021.107565_b0250","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0529-1","article-title":"Proteasome inhibitors as experimental therapeutics of autoimmune diseases","volume":"17","author":"Verbrugge","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2021.107565_b0255","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024523","article-title":"Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial","volume":"9","author":"Kohler","year":"2019","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.intimp.2021.107565_b0260","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pharmthera.2005.01.004","article-title":"The clinical potential of chemokine receptor antagonists","volume":"107","author":"Ribeiro","year":"2005","journal-title":"Pharmacol. Ther."},{"issue":"6483","key":"10.1016\/j.intimp.2021.107565_b0265","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1126\/science.aaz9356","article-title":"Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab","volume":"367","author":"Roug\u00e9","year":"2020","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.intimp.2021.107565_b0270","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2021.107565_b0275","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s10067-020-04996-7","article-title":"Effects of rituximab therapy on B cell differentiation and depletion","volume":"39","author":"Bergantini","year":"2020","journal-title":"Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107565_b0280","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc\u03b3RIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.intimp.2021.107565_b0285","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2011-05-351411","article-title":"Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism","volume":"118","author":"Veeramani","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2021.107565_b0290","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13075-019-2054-0","article-title":"Activation of natural killer cells by rituximab in granulomatosis with polyangiitis","volume":"21","author":"Urlaub","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2021.107565_b0295","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"Shan","year":"1998","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.intimp.2021.107565_b0300","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s002620050016","article-title":"Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells","volume":"48","author":"Shan","year":"2000","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2021.107565_b0305","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","volume":"13","author":"Cerny","year":"2002","journal-title":"Anticancer Drugs"},{"issue":"47","key":"10.1016\/j.intimp.2021.107565_b0310","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.intimp.2021.107565_b0315","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ijc.2910270607","article-title":"Monoclonal anticolon carcinoma antibodies in complement-dependent cytotoxicity","volume":"27","author":"Herlyn","year":"1981","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2021.107565_b0320","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jim.2019.03.001","article-title":"A novel method for determining antibody-dependent cellular phagocytosis","volume":"468","author":"Kamen","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.intimp.2021.107565_b0325","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/j.biopha.2018.11.121","article-title":"The applications of anti-CD20 antibodies to treat various B cells disorders","volume":"109","author":"Payandeh","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.intimp.2021.107565_b0330","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","article-title":"The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction","volume":"99","author":"Byrd","year":"2002","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.intimp.2021.107565_b0335","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell\u2013mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.intimp.2021.107565_b0340","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2010-07-296913","article-title":"Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies","volume":"117","author":"Alduaij","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2021.107565_b0345","unstructured":"D.G. Maloney, Anti-CD20 antibody therapy for B-cell lymphomas, mai 23, 2012, doi: 10.1056\/NEJMct1114348. https:\/\/www.nejm.org\/doi\/10.1056\/NEJMct1114348 (consult\u00e9 le janv. 27, 2021)."},{"issue":"9","key":"10.1016\/j.intimp.2021.107565_b0350","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1590\/1806-9282.63.09.810","article-title":"CD20 role in pathophysiology of Hodgkin\u2019s disease","volume":"63","author":"Santos","year":"2017","journal-title":"Rev. Assoc. M\u00e9dica Bras."},{"issue":"3","key":"10.1016\/j.intimp.2021.107565_b0355","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1365-2141.2008.07193.x","article-title":"A requirement for calcium in the caspase-independent killing of Burkitt lymphoma cell lines by Rituximab","volume":"142","author":"Daniels","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2021.107565_b0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/4231561","article-title":"Assessment of confirmed clinical hypersensitivity to rituximab in patients affected with B-cell neoplasia","volume":"2020","author":"Novelli","year":"2020","journal-title":"Adv. Hematol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107565_b0365","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2006.061002","article-title":"Consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"66","author":"Smolen","year":"2006","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2021.107565_b0370","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.blre.2008.02.001","article-title":"Management of viral hepatitis in hematologic malignancies","volume":"22","author":"Firpi","year":"2008","journal-title":"Blood Rev."},{"issue":"6","key":"10.1016\/j.intimp.2021.107565_b0375","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/bjd.13355","article-title":"Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses","volume":"171","author":"Keith","year":"2014","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107565_b0380","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2018-04-848044","article-title":"Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy","volume":"133","author":"Kusumoto","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2021.107565_b0385","article-title":"Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy","author":"Koo","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2021.107565_b0390","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","author":"Smolen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2021.107565_b0395","first-page":"41","article-title":"Alrehaily, risk of tuberculosis reactivation with rituximab therapy","volume":"11","author":"Alkadi","year":"2017","journal-title":"Int. J. Health Sci."},{"issue":"6","key":"10.1016\/j.intimp.2021.107565_b0400","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/10428190500473113","article-title":"Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments","volume":"47","author":"Cattaneo","year":"2006","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.intimp.2021.107565_b0405","doi-asserted-by":"crossref","DOI":"10.5070\/D34NS1K655","article-title":"A review of rituximab in cutaneous medicine","volume":"12","author":"Scheinfeld","year":"2006","journal-title":"Dermatol. Online J."},{"issue":"3","key":"10.1016\/j.intimp.2021.107565_b0410","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/ced.13726","article-title":"Early-onset neutropenia after rituximab therapy for bullous pemphigoid","volume":"44","author":"Adler","year":"2019","journal-title":"Clin. Exp. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2021.107565_b0415","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","article-title":"Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","volume":"6","author":"Hertl","year":"2008","journal-title":"JDDG"},{"issue":"4","key":"10.1016\/j.intimp.2021.107565_b0420","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40257-017-0264-2","article-title":"A review of its diagnosis, associations and treatment","volume":"18","author":"Bernard","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2021.107565_b0425","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/cc11304","article-title":"Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective","volume":"16","author":"Kasi","year":"2012","journal-title":"Crit. Care"},{"issue":"6","key":"10.1016\/j.intimp.2021.107565_b0430","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera\u00ae)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat. Rev."},{"issue":"10","key":"10.1016\/j.intimp.2021.107565_b0435","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","volume":"16","author":"Ghielmini","year":"2005","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107565_b0440","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/ard.2010.137216","article-title":"EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"70","author":"van Assen","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2021.107565_b0445","doi-asserted-by":"crossref","first-page":"131","DOI":"10.18773\/austprescr.2016.053","article-title":"Rituximab in autoimmune diseases","volume":"39","author":"Randall","year":"2016","journal-title":"Aust. Prescr."},{"key":"10.1016\/j.intimp.2021.107565_b0450","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.2147\/DDDT.S139248","article-title":"Current perspective on rituximab in rheumatic diseases","volume":"11","author":"Schioppo","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.intimp.2021.107565_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102364","article-title":"Sj\u00f6gren\u2019s syndrome: old and new therapeutic targets","volume":"110","author":"Mavragani","year":"2020","journal-title":"J. Autoimmun."},{"issue":"9","key":"10.1016\/j.intimp.2021.107565_b0460","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti\u2013tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.intimp.2021.107565_b0465","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1016\/S2665-9913(20)30033-3","article-title":"Lessons for rituximab therapy in patients with rheumatoid arthritis","volume":"2","author":"Garcia-Montoya","year":"2020","journal-title":"Lancet Rheumatol."},{"issue":"8","key":"10.1016\/j.intimp.2021.107565_b0470","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1136\/annrheumdis-2013-203480","article-title":"Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial","volume":"73","author":"Mariette","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.intimp.2021.107565_b0475","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1097\/MPH.0000000000001276","article-title":"Weekly rituximab followed by monthly rituximab treatment for autoimmune disease associated with RAS-associated autoimmune leukoproliferative disease","volume":"40","author":"Toyoda","year":"2018","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2021.107565_b0480","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/rheumatology\/keq116","article-title":"Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)","volume":"49","author":"Rubbert-Roth","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2021.107565_b0485","doi-asserted-by":"crossref","unstructured":"L. Garcia-Montoya, M.Y. MD Yusof, J.B. Candelier, A. Rawstron, E. Vital, P. Emery, SAT0144 understanding the long-term outcome of rituximab \u2013 implications for management, in: Saturday, 15 June 2019, 2019, pp. 1143.1\u20131143, doi: 10.1136\/annrheumdis-2019-eular.7601.","DOI":"10.1136\/annrheumdis-2019-eular.7601"},{"issue":"3","key":"10.1016\/j.intimp.2021.107565_b0490","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/rheumatology\/kex446","article-title":"Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection","volume":"57","author":"Henry","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2021.107565_b0495","doi-asserted-by":"crossref","first-page":"l67","DOI":"10.1136\/bmj.l67","article-title":"Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study","author":"Gottenberg","year":"2019","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.intimp.2021.107565_b0500","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/1756-185X.12845","article-title":"Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study","volume":"19","author":"Pascart","year":"2016","journal-title":"Int. J. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2021.107565_b0505","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase ii\/iii systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.intimp.2021.107565_b0510","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2021.107565_b0515","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3389\/fmed.2020.00316","article-title":"B cell therapy in systemic lupus erythematosus: from rationale to clinical practice","volume":"7","author":"Parodis","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2021.107565_b0520","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2021.107565_b0525","doi-asserted-by":"crossref","DOI":"10.1002\/art.38074","article-title":"Elevated serum B-cell activating factor (BAFF \/ BLyS) is associated with rising anti-dsDNA antibody levels and flare following B-cell depletion therapy in systemic lupus erythematosus: BAFF and SLE Relapse Following Rituximab","author":"Carter","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2021.107565_b0530","doi-asserted-by":"crossref","unstructured":"C. Aranow et al., FRI0305 Phase 2 trial of induction therapy with anti-cd20 (RITUXIMAB) followed by maintenance therapy with anti-baff (BELIMUMAB) in patients with active lupus nephritis, in: FRIDAY, 15 JUNE 2018, 2018, p. 690.1\u2013690, doi: 10.1136\/annrheumdis-2018-eular.5711.","DOI":"10.1136\/annrheumdis-2018-eular.5711"},{"issue":"3","key":"10.1016\/j.intimp.2021.107565_b0535","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025687","article-title":"Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol","volume":"9","author":"Teng","year":"2019","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.intimp.2021.107565_b0540","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2021.107565_b0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106389","article-title":"Safety and efficacy of Rituximab in systemic sclerosis: a systematic review and meta-analysis","volume":"83","author":"Tang","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"8","key":"10.1016\/j.intimp.2021.107565_b0550","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11940-020-00632-6","article-title":"Myasthenia Gravis Treatment Updates","volume":"22","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Curr. Treat. Options Neurol."},{"issue":"8","key":"10.1016\/j.intimp.2021.107565_b0555","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.intimp.2021.107565_b0560","doi-asserted-by":"crossref","unstructured":"G. Nepal et al., Efficacy and safety of rituximab in autoimmune encephalitis: a meta-analysis, Acta Neurol. Scand., doi: 10.1111\/ane.13291.","DOI":"10.1111\/ane.13291"},{"issue":"10","key":"10.1016\/j.intimp.2021.107565_b0565","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/qjmed\/hcu094","article-title":"Hypogammaglobulinaemia after rituximab treatment\u2013incidence and outcomes","volume":"107","author":"Makatsori","year":"2014","journal-title":"QJM"},{"issue":"1","key":"10.1016\/j.intimp.2021.107565_b0570","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.iac.2018.08.005","article-title":"Secondary hypogammaglobulinemia","volume":"39","author":"Kaplan","year":"2019","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"10.1016\/j.intimp.2021.107565_b0575","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2021.107565_b0580","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3324\/haematol.2019.218883","article-title":"Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?","volume":"104","author":"Lucchini","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.intimp.2021.107565_b0585","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaip.2019.07.032","article-title":"Rituximab unveils hypogammaglobulinemia and immunodeficiency in children with autoimmune cytopenia","volume":"8","author":"Ottaviano","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.intimp.2021.107565_b0590","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12948-019-0113-3","article-title":"Immunosuppressive therapy with rituximab in common variable immunodeficiency","volume":"17","author":"Pecoraro","year":"2019","journal-title":"Clin. Mol. Allergy"},{"issue":"1","key":"10.1016\/j.intimp.2021.107565_b0595","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2052-1839-13-4","article-title":"Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with Rituximab","volume":"13","author":"Mogensen","year":"2013","journal-title":"BMC Blood Disord."},{"issue":"3","key":"10.1016\/j.intimp.2021.107565_b0600","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jaip.2018.10.041","article-title":"Efficacy of rituximab as a single-agent therapy for the treatment of granulomatous and lymphocytic interstitial lung disease in patients with common variable immunodeficiency","volume":"7","author":"Cereser","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"5","key":"10.1016\/j.intimp.2021.107565_b0605","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/j.chest.2019.01.034","article-title":"Rituximab monotherapy for common variable immune deficiency-associated granulomatous-lymphocytic interstitial lung disease","volume":"155","author":"Ng","year":"2019","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.intimp.2021.107565_b0610","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaip.2014.06.003","article-title":"Rituximab and immune deficiency: case series and review of the literature","volume":"2","author":"Kaplan","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.intimp.2021.107565_b0615","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/16078454.2020.1740430","article-title":"The association between antinuclear antibody and response to rituximab treatment in adult patients with primary immune thrombocytopenia","volume":"25","author":"Wang","year":"2020","journal-title":"Hematology"},{"issue":"4","key":"10.1016\/j.intimp.2021.107565_b0620","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1179\/1607845412Y.0000000073","article-title":"Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: report of four cases","volume":"18","author":"Peque\u00f1o-Lu\u00e9vano","year":"2013","journal-title":"Hematology"},{"issue":"3","key":"10.1016\/j.intimp.2021.107565_b0625","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2141.2009.07987.x","article-title":"Successful treatment of autoimmune and lymphoproliferative complications of patients with intrinsic B-cell immunodeficiencies with Rituximab","volume":"148","author":"Hennig","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107565_b0630","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/bjh.15263","article-title":"Management of post-transplant lymphoproliferative disorders","volume":"182","author":"DeStefano","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107565_b0635","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/ejh.12904","article-title":"DA-EPOCH-R for post-transplant lymphoproliferative disorders","volume":"99","author":"DeStefano","year":"2017","journal-title":"Eur. J. Haematol."},{"issue":"7","key":"10.1016\/j.intimp.2021.107565_b0640","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00277-020-04084-5","article-title":"Lymphopenia at diagnosis predicts survival of patients with immunodeficiency-associated lymphoproliferative disorders","volume":"99","author":"Watanabe","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.intimp.2021.107565_b0645","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fonc.2019.00109","article-title":"Epstein barr virus associated B-cell lymphomas and iatrogenic lymphoproliferative disorders","volume":"9","author":"Crombie","year":"2019","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2021.107565_b0650","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1111\/j.1600-6143.2005.01098.x","article-title":"Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD): post-transplant lymphoproliferative disorder (PTLD)","volume":"5","author":"Oertel","year":"2005","journal-title":"Am. J. Transplant."},{"issue":"12","key":"10.1016\/j.intimp.2021.107565_b0655","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1080\/10428190600908349","article-title":"Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: a United Kingdom Children\u2019s Cancer Study Group (UKCCSG) retrospective review","volume":"47","author":"Messahel","year":"2006","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.intimp.2021.107565_b0660","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/ejh.12782","article-title":"First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study","volume":"98","author":"Mart\u00ednez-Calle","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.intimp.2021.107565_b0665","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1093\/annonc\/11.suppl_1.S113","article-title":"Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients","volume":"11","author":"Milpied","year":"2000","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2021.107565_b0670","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1432-2277.2006.00284.x","article-title":"Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab","volume":"19","author":"Svoboda","year":"2006","journal-title":"Transpl. Int."},{"issue":"12","key":"10.1016\/j.intimp.2021.107565_b0675","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.intimp.2021.107565_b0680","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2011-01-329177","article-title":"Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia","volume":"118","author":"Parikh","year":"2011","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.intimp.2021.107565_b0685","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell\u2013targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2021.107565_b0690","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.intimp.2021.107565_b0695","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000463","article-title":"Monitoring B-cell repopulation after depletion therapy in neurologic patients","volume":"5","author":"Ellwardt","year":"2018","journal-title":"Neurol. - Neuroimmunol. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.intimp.2021.107565_b0700","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13075-017-1306-0","article-title":"B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients","volume":"19","author":"Thiel","year":"2017","journal-title":"Arthritis Res. Ther."},{"issue":"12","key":"10.1016\/j.intimp.2021.107565_b0705","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/ard.2007.083162","article-title":"Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus","volume":"67","author":"Albert","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.intimp.2021.107565_b0710","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/art.22019","article-title":"Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis","volume":"54","author":"Roll","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.intimp.2021.107565_b0715","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/ard.2011.153601","article-title":"Rituximab for refractory granulomatosis with polyangiitis (Wegener\u2019s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations","volume":"71","author":"Holle","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2021.107565_b0720","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","article-title":"Rituximab for refractory WEGENER\u2019S granulomatosis: report of a prospective, open-label pilot trial","volume":"173","author":"Keogh","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.intimp.2021.107565_b0725","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"van Vollenhoven","year":"2010","journal-title":"J. Rheumatol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921002010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921002010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:28:48Z","timestamp":1761586128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921002010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":145,"alternative-id":["S1567576921002010"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107565","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clinical efficacy of Rituximab administration in autoimmunity disorders, primary immunodeficiency diseases and malignancies","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107565","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107565"}}